Intracranial Aneurysms Clinical Trial
Official title:
Giant Intracranial Aneurysm Registry
The purpose of this study is to generate detailed insight into which therapies of giant intracranial aneurysms are being conducted, to document the natural history and the outcome of treatment over 5 years after inclusion into the Registry and to follow imaging data of giant aneurysms over years after diagnosis.
Definition of aims, eligibility of patients and data flow
In August 2009 a steering committee was appointed and its first meeting took place in Berlin.
Here the aims of the registry were defined as follows: 1) To generate detailed insight into
which therapies are being conducted. 2) To document the natural history of patients and
follow it over years after diagnosis. 3) To follow imaging data of giant aneurysms over years
after diagnosis, whether treated conservatively or not. 4) To expand the register into
several disciplines (by inviting neuroradiologic and neurologic centers to join) and
internationally.
Inclusion criteria are a) the diagnosis of a giant intracranial aneurysm by CT, MRI or
regular angiography, b) age 18 years and older and c) informed consent. There are no
exclusion criteria. If a patient is not able to give informed consent due to his or her
clinical situation, the legal representative of the patient (e.g. family member) will be
informed and asked to sign the consent form on behalf of the patient.
Patients are recruited consecutively in responsibility of each center. In addition to the
prospective part there is a retrospective part in which patients are included that were
admitted after January 2006. Data are gathered at admission, discharge and 1/3/5 years after
discharge. Starting from February 2010 a 9-month pilot phase was conducted in order to
identify and correct possible problems of data acquisition.
Development of a study protocol
Relevant variables were discussed on the basis of existing literature on giant intracranial
aneurysms. All variables were chosen so that they can be determined in a routine clinical
context even in small centers with minimal technical equipment. Data collection was decided
to be carried out using a modular structure, consisting of a basic module and additional
modules for specific research questions.
The steering committee decided on the content of a mandatory basic data collection for all
centers. This basic module was designed to keep the amount of variables at a minimum so that
data collection can be conducted as safely and quickly as possible by physicians of all
disciplines. It focuses on the clinical course between initial presentation and discharge but
also includes data on patient history, such as risk factors and possible prior aneurysm
therapy. A neurological examination of cranial nerve functions, motor capability and speech
is conducted initially, at discharge and during 3 mandatory follow-up examinations. At each
examination the patients' physical condition is recorded using internationally accepted and
reliable grading systems. The investigator is asked to not only record a clinical diagnosis,
such as epileptic seizure or incidental finding, but also use imaging data to produce a
radiological diagnosis and characterize the aneurysm regarding its location, size, shape and
structure. The mode of therapy is documented choosing between conservative, surgical and
endovascular options and combinations thereof. Possible complications are recorded as well as
radiologic results of intervention.
Each center is given the option to take part in additional extra modules, which serve as a
basis for spin-off projects resulting from the discussion within the study group. This
comprises for example an imaging module to lead to a better understanding of how giant
intracranial aneurysms develop over time. It will monitor changes in aneurysm configuration
and flow dynamics using 3D-imaging data. A cost module will integrate data on treatment
expenses making it possible to compare the costs of each mode of therapy.
An external review of the study protocol was conducted to ensure high methodological quality
and wide acceptance of the results. For this purpose a preliminary working report was
forwarded to 4 independent experts in the field of neurovascular research. The reviewers were
asked to comment on the appropriateness of the methods, the practicability of our variables
and the coverage of relevant aspects of giant intracranial aneurysm care. The comments of the
external reviewers were gathered and discussed within the steering committee. Based on the
recommendations of the external reviewers, a final revision of the study protocol took place.
Primary hypothesis, study outcome and statistical analyses
The primary hypothesis of the study is that conservative, endovascular and surgical therapy
result in equal aneurysm rupture rates. Therefore primary outcome will be aneurysm rupture
rate at 5 years of follow up.
The sample size calculation is based on the estimated 5-year cumulative rupture rates for
patients with unruptured giant aneurysm given in the ISUIA-Trial. According to their results
we assume a 5-year rupture rate of 0.30 irrespective of which specific treatment is applied.
Because of a lack of data on special rupture rates regarding patients treated with the three
considered methods, sample size calculation was done for one proportion based on precision
analysis. Consequently, a two-sided 95% confidence interval with a width equal to 0.10 is
achieved by a sample size of 320 patients. For the outcomes death or rupture the
corresponding survival functions with 95% confidence intervals will be estimated by the
Kaplan-Meier method. The null-hypotheses of equal survival curves for two treatment groups
will be tested by the Log-Rank test. With documented dates of rupture events the sample size
of 320 calculated above is sufficient to detect moderate effects of possible predictors for
rupture by Cox proportional hazards regression within a secondary analysis. Furthermore we
can model the logit of rupture after 5 years by binary logistic regression detecting possible
moderate to considerable effects of predictors. Therapy (conventional, surgery or
endovascular) will be the main factor of interest for both multivariable analyses.
Patient recruitment / Data storage / Quality assurance
In 2008 patient recruitment began at the Charité Berlin, one year later data from other
centers were included as well, initially only in Germany, later on throughout Europe and
Japan. Patient data are stored using pseudonyms. Centers can either use a fax-based data
inclusion form or a web-based entry form. All data are stored at the Charité - Berlin. For
quality assurance a monitoring visit to the 7 most-including centers was conducted in 2013.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02879175 -
Patients' Follow-up After Subarachnoid Haemorrhage Caused by Ruptured Intracranial Aneurysms
|
||
Completed |
NCT01139892 -
The Canadian UnRuptured Endovascular Versus Surgery Trial (CURES)
|
||
Recruiting |
NCT06411418 -
Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm
|
N/A | |
Completed |
NCT02312856 -
Adjunctive Neurovascular Support for Wide-neck Aneurysm Embolization and Reconstruction
|
N/A | |
Recruiting |
NCT01054391 -
Neurovascular Embolization Cover for Treatment of Intracranial Aneurysms and Carotid/Vertebrobasilar Fistulae
|
N/A | |
Completed |
NCT02657772 -
Ultra Coils From Start to Finish for the Endovascular Repair of Small Intracranial Aneurysms
|
||
Completed |
NCT01465841 -
Study of the Penumbra Coil 400 System to Treat Aneurysm
|
N/A | |
Enrolling by invitation |
NCT05453240 -
Post-Market Surveillance Study to Evaluate the Long-Term Safety and Effectiveness of the LVIS Device
|
||
Completed |
NCT03550638 -
Coil System(Ton-bridgeMT) for Endovascular Embolization of Cranial Aneurysms
|
N/A | |
Terminated |
NCT02122133 -
CARE: A Prospective Multicenter Case Study to Assess Radiation Exposure in Patients Treated With the Penumbra Coil 400
|
||
Completed |
NCT01541254 -
Feasibility Study of the LVIS™ (Low-profile Visualized Intraluminal Support)Device
|
Phase 2/Phase 3 | |
Terminated |
NCT01320306 -
Intracranial Aneurysms and Cognitive Function
|
||
Recruiting |
NCT01084681 -
Efficacy Trial of Intracranial Aneurysm Treatment Using Two Different Endovascular Techniques
|
N/A | |
Completed |
NCT00396981 -
MAPS Trial: Matrix And Platinum Science
|
Phase 4 | |
Completed |
NCT02921711 -
TRAIL: Treatment of Intracranial Aneurysms With LVIS® System
|
||
Recruiting |
NCT01031147 -
Contrast-free Magnetic Resonance Angiography (MRA) at 3.0 T for Intracranial Aneurysm Detection
|
N/A | |
Recruiting |
NCT05636124 -
Kaneka iED Coil System for the Treatment of Wide Necked Ruptured and Unruptured Intracranial Aneurysms
|
N/A | |
Completed |
NCT02921698 -
Safety and Efficacy Analysis of FRED® Embolic Device in Aneurysm Treatment
|
||
Terminated |
NCT01974700 -
Seizure Prophylaxis in Aneurysm Repair
|
Phase 4 | |
Completed |
NCT01801007 -
Pivotal Study of the FRED Stent System in the Treatment of Intracranial Aneurysms
|
N/A |